For hospital pharmacies and institutional buyers

Named-patient access looks different from the pharmacy director's seat. The patient is already under hospital care, the ordering workflow expects a purchase order, the receiving dock expects a cold-chain-documented delivery addressed to the pharmacy, and the P&T committee expects the file to be clean enough that the import decision survives a look from the quality office and, in due course, from an inspector. Reserve Meds is built for that file. We coordinate the US-side sourcing, documentation, and cold-chain logistics, under the clinical authority of the treating physician and within the import pathway your institution uses for named-patient products.

The institutional engagement, in brief

A hospital engagement begins with a short enquiry from the pharmacy director or a delegated pharmacy buyer, usually in parallel with the clinical team's engagement on the same patient. We open a single file that carries through from intake to delivery, so that the prescribing physician, the pharmacy director, and the receiving technician are all referring to one set of serial numbers, one cold-chain log, and one regulatory bundle. Where your institution has a preferred broker or customs agent on the destination side, we work through them. Where you do not, we bring ours, on a named-account basis that respects your existing procurement posture.

The questions a P&T reviewer typically asks

In our experience, a pharmacy and therapeutics reviewer asks a consistent set of questions the first time a named-patient import is brought forward. The first is the provenance of the product: where it is sourced, whether the US chain of custody is DSCSA-compliant, and whether serialisation records are available for the specific lots that will be dispensed. The answer, in our case, is that every unit is acquired through a licensed US specialty wholesaler (McKesson Specialty, AmerisourceBergen / Cencora Specialty, or Cardinal Health Specialty) with a full DSCSA transaction history, transaction information, and transaction statement on file and available to the reviewer on request.

The second is the regulatory posture on the destination side. A reviewer wants to see the specific pathway that the import is travelling, whether it is a ministry-of-health named-patient authorisation, a hospital-formulary unregistered-product route, or an institutional compassionate-use mechanism. We prepare that file, in English and in the local language where required, and share it with the reviewer ahead of the import decision. The third is the cold-chain integrity plan, which we cover below. The fourth is the pharmacovigilance and adverse-event reporting commitment, which we accept as part of our standard engagement.

The receiving protocol at the dock

Physical delivery is addressed to the hospital pharmacy, under the name of a receiving pharmacist or technician nominated by the pharmacy director. The shipment arrives in validated thermal packaging with an embedded temperature logger; on receipt, the pharmacy inspects the logger, confirms the seal, and signs for acceptance or places the shipment on quarantine pending review. Any unit that exceeded its approved excursion profile is replaced at our cost. Reserve Meds provides a receiving checklist that the pharmacy can adopt into its existing SOP without modification; for institutions with a more bespoke receiving standard, we align our packout to the institution's protocol in advance.

The documentation package the pharmacy receives

Each shipment is accompanied by a dossier that includes the US dispensing record from Altima Care, the DSCSA transaction history for the lot, the cold-chain log from pickup through delivery, the export and import paperwork filed on both sides, a copy of the treating physician's prescription and medical-rationale letter (with patient identifiers handled per your preferred redaction policy), and the regulatory correspondence for the named-patient authorisation. The pharmacy retains the dossier as part of its dispensing record; we retain a copy under our own record-retention schedule and make it available to the institution on written request.

Invoice, payment, and the cash-pay posture

Reserve Meds operates on a cash-pay basis. We do not bill insurance, and we do not coordinate reimbursement from manufacturers or payers on the destination side. Institutional engagements are invoiced on a named-patient basis against a standard hospital purchase order, with net terms negotiated at account opening. Payment is accepted by wire transfer or institutional credit card; we do not accept cryptocurrency or payment from any jurisdiction subject to comprehensive sanctions. Pricing is quoted for the specific indication and quantity, is valid for a defined period, and is not published on this site. Where a manufacturer patient-assistance programme or charitable-foundation pathway is relevant, we will signpost it; we do not evaluate patient creditworthiness or run financing.

Enterprise briefing and a named account

For institutions expecting repeat named-patient activity, we offer a short enterprise briefing, either virtual or on site, in which our pharmacist-in-charge and our regulatory lead walk the pharmacy and the P&T committee through the sourcing, documentation, and handover protocol in advance of the first case. Institutions that complete the briefing move to a named account with a single point of contact on our side and a published response-time commitment. We prefer to do the hard work of alignment once, before the first urgent case, rather than during it.

What we will not do

We do not source controlled substances, we do not act outside the receiving country's published named-patient or unregistered-product pathway, and we do not supply without a named prescriber of record. We do not share patient information with any party other than the treating physician, the receiving institution, and the regulator, with the standard legal exceptions for pharmacovigilance reporting. We will tell you plainly when a request falls outside our scope.

Reviewed 2026-04-22 by Reserve Meds's AI clinical and regulatory review agents. Human pharmacist-in-charge: Altima Care. Next scheduled review: 2026-10-22.